Home/Pipeline/A197

A197

Dry Eye Disease

Phase 2Active

Key Facts

Indication

Dry Eye Disease

Phase

Phase 2

Status

Active

Company

Aramis Biosciences

About Aramis Biosciences

Aramis Biosciences is a private, clinical-stage biotech targeting the significant unmet need in ocular surface diseases, particularly dry eye disease (DED). The company's approach is rooted in foundational research from Harvard Medical School's Schepens Eye Research Institute, focusing on modulating specific pro-inflammatory T helper cells implicated in DED pathogenesis. Its lead asset, A197, has completed enrollment in a Phase II proof-of-concept trial, with topline data expected in Q1 2023. Aramis is backed by a team of seasoned pharmaceutical executives and renowned scientific advisors, supported by strategic investors like Santen Ventures and Safar Partners.

View full company profile

Therapeutic Areas

Ophthalmology Immunology

Other Dry Eye Disease Drugs

Drug	Company	Phase	Status
Avarept® Ophthalmic suspension 0.3%	Senju Pharmaceutical	Approved	Active
Dry Eye Care Portfolio	YD Bio	Commercial	Active
Dry Eye Studies	Oculus Research	Not Applicable (Service Provider)	Active
MediPrint Lens (Dry Eye)	MediPrint Ophthalmics	Pre-clinical/Research	Active
Tivanisiran	Sylentis	Phase 2/3	Active
KM102	Theratome Bio	Pre-clinical	Active
iTEAR®100 Commercialization	Olympic Ophthalmics	Commercial	Active
HydraD	EyeD Pharma	Pre-Clinical	Active
ST-100 (Vezocolmitide)	Stuart Therapeutics	Phase 3	Active
CyclASol®	Novaliq	Approved	Active
NovaTears®	Novaliq	Commercial	Active
NovaTears® +Omega-3	Novaliq	Commercial	Active